recombinant protein subunit vaccine candidates resvax  (Novavax Inc)

Journal: NPJ Vaccines

Article Title: Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

doi: 10.1038/s41541-024-00901-4

Figure Lengend Snippet: a The experimental design is shown; Mouse pups were inoculated at weaning with 5 µg SARS-CoV-2 recombinant protein (RP) vaccine b , c adjuvanted with PBS (RP-PBS), AddavaxTM (RP-Ad), or LNP (RP-LNP) or SARS-CoV-2 mRNA-LNP vaccine d , e at 1 µg, 5 µg, or 10 µg. b – e Sera were collected from mouse pups at indicated time points after weaning/vaccination and SARS-CoV-2 full length Spike (S) protein-specific IgG concentrations b , d and IgM concentrations c , e were measured by ELISA. Each point represents the geometric mean with error bars indicating 95% confidence interval (CI) of the geometric mean. Mouse groups were n = 5 (RP vaccinated groups) or n = 6 (mRNA vaccinated groups). Sample IgG and IgM concentrations were plotted to a standard curve of known concentrations of a S-specific IgG monoclonal antibody and are reported as arbitrary units (AU)/mL. Data are shown as geometric mean concentrations with 95% confidence intervals. All panels show results of one experiment that is representative of two independent biological replicates. Group geometric mean IgG concentrations were compared at 4 weeks and 8 weeks post-vaccination to corresponding within-group 1 week concentrations by repeated measures (RM) one-way ANOVA with Tukey’s post hoc test (* indicates p < 0.05, ** indicates p < 0.01). Schematic for a created with Biorender.

Article Snippet: Recombinant spike protein subunit vaccines were prepared by diluting 5 μg recombinant spike protein in 50 μL diluent; diluent for Addavax TM -adjuvanted vaccines consisting of 25 μL PBS and 25 μL Addavax TM (Invivogen, San Diego, CA) and diluent for lipid nanoparticle-adjuvanted vaccines consisted of a concentration of LNP corresponding to the mRNA-LNP vaccine brought to a total volume of 50 μL with PBS.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay

Journal: NPJ Vaccines

Article Title: Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

doi: 10.1038/s41541-024-00901-4

Figure Lengend Snippet: a The experimental design is shown; Female mice were mated with males and then were inoculated at day 5 after introduction of males with SARS-CoV-2 mRNA-LNP vaccine at 0.1 µg, 1 µg, or 5 µg. b , c . b Sera were collected from mouse pups at indicated time points after weaning/vaccination and SARS-CoV-2 full length Spike (S) protein-specific IgG concentrations were measured by ELISA. One phase-decay was fitted to IgG data (R 2 > 0.90 for all groups) with each point representing a single mouse pup and each line representing the decay curve for one dose group (0.1 µg n = 2; 1 µg n = 12; 5 µg n = 7). c Dams were vaccinated with 5 µg mRNA-LNP and serum was collected from dams ( n = 6) and pups ( n = 48) at day of weaning. Each point represents the geometric mean with error bars indicating 95% confidence interval (CI) of the geometric mean. Sample IgG concentrations were plotted to a standard curve of known concentrations of a S-specific IgG monoclonal antibody and are reported as arbitrary units (AU)/mL. Data are shown as geometric mean concentrations with 95% confidence intervals (* indicates p < 0.05 by unpaired two-tailed Student’s T test). Schematic for Figure a created with Biorender.

Article Snippet: Recombinant spike protein subunit vaccines were prepared by diluting 5 μg recombinant spike protein in 50 μL diluent; diluent for Addavax TM -adjuvanted vaccines consisting of 25 μL PBS and 25 μL Addavax TM (Invivogen, San Diego, CA) and diluent for lipid nanoparticle-adjuvanted vaccines consisted of a concentration of LNP corresponding to the mRNA-LNP vaccine brought to a total volume of 50 μL with PBS.

Techniques: Enzyme-linked Immunosorbent Assay, Two Tailed Test

Journal: NPJ Vaccines

Article Title: Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

doi: 10.1038/s41541-024-00901-4

Figure Lengend Snippet: a The experimental design is shown; Female mice were mated with males and then were inoculated at day 5 after introduction of males with SARS-CoV-2 mRNA-LNP vaccine (5 µg) or PBS and pups were vaccinated at weaning with PBS, SARS-CoV-2 recombinant protein (RP) with Addavax (RP-Ad) or empty lipid nanoparticle (RP-LNP), or SARS-CoV-2 mRNA vaccine (mRNA-LNP). b – e Sera were collected from mouse pups at indicated time points after weaning/vaccination and SARS-CoV-2 full length Spike (S) protein-specific IgG concentrations were measured by ELISA. For each vaccine condition ( b , PBS; c , mRNA-LNP; d , RP-Ad; e RP-LNP; n = 4-6 mice per group) at each time point, geometric mean IgG concentrations were compared between the matAb+ and matAb- groups by one-way ANOVA with post hoc Šidák test. Each point represents the geometric mean with 95% confidence intervals. f , g Column graphs depict SARS-CoV-2 IgG concentrations for matAb- f and matAb+ g mice at 18 weeks post-vaccination for each vaccine condition, with each point representing a single mouse and central bars representing geometric mean concentration and 95% CI. Group geometric mean IgG concentrations were compared by one-way ANOVA with Tukey’s post hoc test with significance level of group comparison indicated by nested brackets. For all panels, sample IgG concentrations were plotted to a standard curve of known concentrations of a SARS-CoV-2 IgG monoclonal antibody and are reported as arbitrary units (AU)/mL with samples for which IgG was below the threshold of detection (TOD, represented by horizontal dotted lines) imputed to half the TOD (represented by the x axis). Central points/bars and error bars for all panels represent geometric mean concentrations with 95% confidence intervals. Significance levels for statistical hypothesis testing are indicated (* indicates p < 0.05, ** indicates p < 0.01, ns indicates p ≥ 0.05). All panels show results of one experiment that is representative of two independent biological replicates. Schematic for a created with Biorender.

Article Snippet: Recombinant spike protein subunit vaccines were prepared by diluting 5 μg recombinant spike protein in 50 μL diluent; diluent for Addavax TM -adjuvanted vaccines consisting of 25 μL PBS and 25 μL Addavax TM (Invivogen, San Diego, CA) and diluent for lipid nanoparticle-adjuvanted vaccines consisted of a concentration of LNP corresponding to the mRNA-LNP vaccine brought to a total volume of 50 μL with PBS.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Concentration Assay, Comparison

Journal: NPJ Vaccines

Article Title: Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

doi: 10.1038/s41541-024-00901-4

Figure Lengend Snippet: Female mice were mated with males and then were inoculated at day 5 after introduction of males with SARS-CoV-2 mRNA-LNP vaccine (5 µg) or PBS and pups were vaccinated at weaning with PBS, SARS-CoV-2 recombinant protein (RP) with Addavax (RP-Ad) or empty lipid nanoparticle (RP-LNP), or SARS-CoV-2 mRNA vaccine (mRNA-LNP). Sera were collected from mouse pups at 4 weeks after weaning/vaccination and neutralization efficacy measured by focus reduction neutralization test (FRNT) of pseudotyped vesicular stomatitis virus (VSV) expressing SARS-CoV-2 D614G spike glycoprotein. Column graphs depict FRNT50 for matAb- a and matAb+ b mice for each vaccine condition, with each point representing a single mouse and central bars representing geometric mean concentration and 95% CI. c Presents all groups on a single column graph for ease of depiction of within-vaccine condition comparisons of matAb- and matAb- mice. Group geometric mean IgG concentrations were compared by one-way ANOVA with Tukey’s post hoc test with significance level of group comparison indicated by nested brackets. Samples for which no neutralization was detected at the lowest dilution were imputed to half the TOD (dotted line). Significance levels for statistical hypothesis testing are indicated (* indicates p < 0.05, ** indicates p < 0.01, ns indicates p ≥ 0.05).

Article Snippet: Recombinant spike protein subunit vaccines were prepared by diluting 5 μg recombinant spike protein in 50 μL diluent; diluent for Addavax TM -adjuvanted vaccines consisting of 25 μL PBS and 25 μL Addavax TM (Invivogen, San Diego, CA) and diluent for lipid nanoparticle-adjuvanted vaccines consisted of a concentration of LNP corresponding to the mRNA-LNP vaccine brought to a total volume of 50 μL with PBS.

Techniques: Recombinant, Neutralization, Virus, Expressing, Concentration Assay, Comparison

Journal: Vaccines

Article Title: Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines

doi: 10.3390/vaccines13020097

Figure Lengend Snippet: Current (as of November 2024) approval status of RSV vaccines for the prevention of RSV-LRTD in Europe and the United States. According to the updated recommendations by the US Advisory Committee on Immunization Practices (ACIP), a single dose of any FDA-approved RSV vaccine is recommended for all adults aged ≥75 years and for adults aged 60–74 years who are at increased risk for severe RSV disease, while no additional doses are recommended for adults who have previously received an RSV vaccine [ 50 ].

Article Snippet: Equal amounts of pre-F RSV-A and RSV-B antigens and no adjuvant are contained in Pfizer’s Abrysvo recombinant protein subunit vaccine ( ).

Techniques: Vaccines

Journal: Vaccines

Article Title: Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines

doi: 10.3390/vaccines13020097

Figure Lengend Snippet: Efficacy of the three approved vaccines against RSV-associated LRTD in older adults.

Article Snippet: Equal amounts of pre-F RSV-A and RSV-B antigens and no adjuvant are contained in Pfizer’s Abrysvo recombinant protein subunit vaccine ( ).

Techniques: Vaccines

Journal: Viruses

Article Title: Detections of Rabbit Hemorrhagic Disease Virus 2 (RHDV2) Following the 2020 Outbreak in Wild Lagomorphs across the Western United States

doi: 10.3390/v16071106

Figure Lengend Snippet: Wild lagomorphs tested for RHDV2 by RT-qPCR in the U.S. between March 2020 and March 2024.

Article Snippet: A recombinant subunit protein RHDV2 vaccine (developed by Medgene Labs [Brookings, South Dakota, U.S.]) is available for use by licensed veterinarians in 44 U.S. states [ ], and challenge studies showed a 0% mortality rate for vaccinated domestic rabbits ( Oryctolagus cuniculus ) [ ].

Techniques:

Journal: Viruses

Article Title: Detections of Rabbit Hemorrhagic Disease Virus 2 (RHDV2) Following the 2020 Outbreak in Wild Lagomorphs across the Western United States

doi: 10.3390/v16071106

Figure Lengend Snippet: Detections of RHDV2 by U.S. County and genus during: ( a ) entire outbreak period, 2020–2024; ( b ) 2020; ( c ) 2021; ( d ) 2022; ( e ) 2023; ( f ) 2024. Map ( a ) is the composite of maps ( b – f ). More than one detection per genus may be represented in each positive county. Each mapped year represents a 12-month calendar year except 2020 (Mar–Dec) and 2024 (Jan–Mar).

Article Snippet: A recombinant subunit protein RHDV2 vaccine (developed by Medgene Labs [Brookings, South Dakota, U.S.]) is available for use by licensed veterinarians in 44 U.S. states [ ], and challenge studies showed a 0% mortality rate for vaccinated domestic rabbits ( Oryctolagus cuniculus ) [ ].

Techniques:

Journal: Viruses

Article Title: Detections of Rabbit Hemorrhagic Disease Virus 2 (RHDV2) Following the 2020 Outbreak in Wild Lagomorphs across the Western United States

doi: 10.3390/v16071106

Figure Lengend Snippet: Monthly U.S. RHDV2 detections by year in wild lagomorphs from March 2020 to March 2024. Each calendar year is represented as a uniquely colored line.

Article Snippet: A recombinant subunit protein RHDV2 vaccine (developed by Medgene Labs [Brookings, South Dakota, U.S.]) is available for use by licensed veterinarians in 44 U.S. states [ ], and challenge studies showed a 0% mortality rate for vaccinated domestic rabbits ( Oryctolagus cuniculus ) [ ].

Techniques: